The secretome of adipose-derived mesenchymal stem cells attenuates epithelial-mesenchymal transition in human corneal epithelium. 2019

Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
Department of Stem Cells and Applied Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

BACKGROUND Epithelial-mesenchymal transition (EMT) induces the loss of cell-cell interactions in polarized epithelial cells and converts these cells to invasive mesenchymal-like cells. It is also involved in tissue fibrosis including that occurring in some ocular surface diseases such as pterygium and in subepithelial corneal fibrosis in limbal stem cell deficiency. Here, we examined the effects of the secretome of human adipose-derived mesenchymal stem cells (AdMSCs) on EMT in human corneal epithelial cells (CECs). METHODS EMT was induced with transforming growth factor-β (TGF-β) in primary human CECs isolated from the human corneal limbus. The effects of the AdMSC secretome on EMT in these cells or stratified CEC sheets were analyzed by co-cultivation experiments with the addition of AdMSC conditioned-medium. The expression of EMT-related genes and proteins in CECs was analyzed. The superstructure of CECs was observed by scanning electron microscopy. Furthermore, the barrier function of CEC sheets was analyzed by measuring transepithelial electrical resistance (TER). RESULTS The AdMSC secretome was found to suppress EMT-related gene expression and attenuate TGF-β-induced corneal epithelial dysfunction including the dissociation of cell-cell interactions and decreases in TER in constructed CEC sheets. CONCLUSIONS The secretome of AdMSCs can inhibit TGF-β-induced EMT in CECs. These findings suggest that this could be a useful source for the treatment for EMT-related ocular surface diseases.

UI MeSH Term Description Entries

Related Publications

Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
April 2023, Cells,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
January 2021, International journal of chronic obstructive pulmonary disease,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
January 2020, BioMed research international,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
July 2018, Biologicals : journal of the International Association of Biological Standardization,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
August 2022, Cells,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
June 2021, Journal of cellular and molecular medicine,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
March 2020, International journal of molecular sciences,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
September 2013, Current eye research,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
February 2018, Experimental and therapeutic medicine,
Shun Shibata, and Ryuhei Hayashi, and Toru Okubo, and Yuji Kudo, and Koichi Baba, and Yoichi Honma, and Kohji Nishida
October 2014, Journal of nephrology,
Copied contents to your clipboard!